Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mipomersen Extension in FH/Severe Hypercholesterolemia
NCT00694109Phase 3Completed
- Sponsor
- Kastle Therapeutics LLC
- Start
- Apr 2008
- Primary completion
- Sep 2014
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 7
01
Overview
A Phase 3 trial of mipomersen in familial hypercholesterolemia (FH), hypercholesterolemia, sponsored by Kastle Therapeutics LLC. Started Apr 2008; status: completed.
02
Drugs
mipomersen
03
Conditions
familial hypercholesterolemia (FH)hypercholesterolemia
Beyond the preview
Go deeper on NCT00694109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00694109.